本月底法定/註冊股本總額： HKD 400,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0 ...

(Stock Code ⫍֍ջ⽚厍455) NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s) (Note 1) , 29 September 2025 Tianda Pharmaceuticals Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") (Incorporated in the Cayman Islands with limited liability) 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 Notes: 各位非登記股東 （附註1） ： 天大藥業有限公司（「本公司」） － 中期報告2025（「本次公司通訊」）之刊發通知 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站( http://www.tiandapharma.com ) 及香港聯合交易所有限公司（「聯交所」）之網站 ( www.hkexnews.hk ) （「網站版本」）。本公司建議 閣下閱覽本公司本次公司通 ...

The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at http://www.tiandapharma.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications (Note) . NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, 29 Sept ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2025年8月31日 | | --- | | 狀態: 新提交 | 本月底法定/註冊股本總額： HKD 400,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | ...

Group 1 - The company reported revenue of HKD 136.6 million for the six months ending June 30, 2025, compared to HKD 156.1 million for the same period in 2024 [1] - The loss attributable to shareholders increased from HKD 27.2 million in the previous interim period to HKD 33.5 million in the current interim period [1] - The board of directors decided not to declare an interim dividend for the six months ending June 30, 2025, consistent with the previous year [1]

Group 1 - Tian Da Pharmaceutical (00455.HK) announced the resignation of Feng Quanming as a non-executive director due to other work commitments, effective from August 29, 2025 [1] - The company further announced the appointment of Zhu Haomiao as a non-executive director, also effective from August 29, 2025 [1]

Core Viewpoint - Tian Da Pharmaceutical (00455) reported a decline in revenue and an increase in losses for the first half of 2025, indicating financial challenges for the company [1] Financial Performance - The company achieved revenue of HKD 137 million, representing a year-on-year decrease of 12.45% [1] - The loss attributable to shareholders was HKD 33.237 million, which expanded by 22.03% compared to the previous year [1] - The basic loss per share was HKD 0.0155 [1]

Group 1 - Tian Da Pharmaceutical (00455) announced that Mr. Feng Quanming has resigned as a non-executive director due to other work arrangements, effective from August 29, 2025 [1] - Mr. Zhu Haomiao has been appointed as a non-executive director, effective from August 29, 2025 [1]

Group 1 - The company Tian Da Pharmaceutical (00455) reported a revenue of HKD 137 million for the first half of 2025, representing a year-on-year decrease of 12.45% [1] - The company's loss attributable to shareholders widened to HKD 33.237 million, an increase of 22.03% compared to the previous year [1] - The basic loss per share was reported at HKD 1.55 cents [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 非執行董事 鍾濤先生 朱浩淼先生 獨立非執行董事 林日輝先生 （首席獨立非執行董事） 趙崇康先生 冼彥芳博士 董事會設立4個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 卻⫍֍ջ⽚厍00455卼 董事名單與其角色和職能 自2025年8月29日起，天大藥業有限公司董事會（「董事會」）成員載列如下： 執行董事 方文權先生 （董事長兼董事總經理） 呂文生先生 | | 委員會 | | | | | | --- | --- | --- | --- | --- | --- | | | | 審核 | 薪酬 | 提名 | 風險管理 | | 董事 | | 委員會 | 委員會 | 委員會 | 委員會 | | 方文權先生 | | | M | C | M | | 呂文生先生 | | | | | | | | | M | | | | | 朱浩淼先生 | | | | | | | 林日輝先生 ...